Core Viewpoint - The company, HeartLink Medical-B (02160.HK), has announced significant growth in its VitaFow® series of transcatheter aortic valves and delivery systems (TAVI), with a cumulative implantation of nearly 1,300 cases across 35 countries and regions as of the announcement date [1] Group 1: Market Expansion - The projected implantation volume for 2025 is expected to exceed 850 cases, representing an increase of nearly 350% compared to 2024 [1] - In the second half of 2025, the implantation volume is anticipated to grow by over 170% compared to the first half, driven by the commercialization of VitaFowLiberty® following CE mark approval in European countries and continued market share growth in emerging markets in Asia and Latin America [1] Group 2: Strategic Enhancements - The company's board believes that the recent acquisition of Micro-Invasive Cardiac Management will strengthen local channel resources and clinical support systems in mature markets like Europe, significantly improving market access efficiency for TAVI products [1] - The company aims to continuously leverage the synergies from business integration, advance the research and clinical progress of next-generation TAVI products, and enhance its overall competitiveness in the global valve treatment sector [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 本公告乃由微創心通醫療科技有限公司（「本公司」，連同其附屬公司統稱「本 集團」）自願作出，以知會本公司股東及潛在投資者有關本集團最新業務進展。 本公司董事「( 董 事」)會（「董事會」）欣 然 宣 佈， 截 至 本 公 告 之 日， 本 集 團 VitaFow®系列經導管主動脈瓣膜及輸送系統（「TAVI」）已進入全球35個國家及地 區，累計植入量近1,300例。其中，2025年植入量預計將超過850例，較2024年增 長近350%。2025年下半年，得益於VitaFow Liberty®獲得CE證後在歐洲國家商業 化的持續拓展，以及在亞洲和拉美新興市場國家份額的持續提升，植入量較上 半年增長超過170%。 – 1 – 本公司董事會相信，通過近期完成的併購微創心律管理的交易，本集團將進一 步強化在歐洲等成熟市場的本地化渠道資源與臨床支持體系，顯著提升TAVI 產品的新市場准入效率與既有市場的滲透深度。未來 ...